US Broker Ratings

AbCellera Biologics Inc. (ABCL) Stock Analysis: A 160% Potential Upside in the Booming Biotech Sector

AbCellera Biologics Inc. (NASDAQ: ABCL) is making waves in the biotechnology industry with a compelling story for investors seeking high growth potential. With a market capitalization of $1.07 billion, this..

Spyre Therapeutics, Inc. (SYRE) Stock Analysis: A Biotech Bet with a 27% Upside Potential

Spyre Therapeutics, Inc. (SYRE) has emerged as a notable player in the biotechnology sector, focusing on innovative treatments for inflammatory bowel disease (IBD) and rheumatic diseases. With a market capitalization..

OrthoPediatrics Corp. (KIDS) Stock Analysis: Healthcare’s Growth Potential with a 54.97% Upside

OrthoPediatrics Corp. (NASDAQ: KIDS) stands out in the healthcare sector as a key player in the niche market of pediatric orthopedic medical devices. With a market capitalization of $405.98 million,..

EyePoint, Inc. (EYPT) Stock Analysis: Unpacking 179% Potential Upside in Biotech

EyePoint, Inc. (EYPT) is capturing attention in the biotechnology sector with its groundbreaking work in developing therapeutics for serious retinal diseases. With a substantial market cap of $1.12 billion, this..

Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Exploring a Potential 92% Upside with Cutting-Edge Gene Editing

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is at the forefront of the biotechnology sector, leveraging the revolutionary power of gene editing to develop transformative treatments for various diseases. Headquartered in Cambridge,..

PureTech Health plc (PRTC) Stock Analysis: Unpacking a 542.7% Revenue Surge in the Biotech Sector

Investors with a keen eye on the biotech sector may find PureTech Health plc (NASDAQ: PRTC) an intriguing proposition. Based in Boston, Massachusetts, PureTech is charting a compelling course with..

Ardelyx, Inc. (ARDX) Stock Analysis: Exploring a Potential 171% Upside in the Biotechnology Sector

Ardelyx, Inc. (NASDAQ: ARDX) is capturing the attention of investors with its promising potential in the biotechnology sector. Known for its focus on developing innovative therapies for unmet medical needs,..

Upstream Bio, Inc. (UPB) Stock Analysis: Biotechnology Innovator with a 364% Potential Upside

Investors seeking high-growth opportunities in the biotechnology sector may find Upstream Bio, Inc. (NASDAQ: UPB) particularly compelling. This clinical-stage biotechnology company, headquartered in Waltham, Massachusetts, is focused on developing treatments..

Pharvaris N.V. (PHVS) Stock Analysis: A 61% Upside Potential in the Biotech Arena

Pharvaris N.V. (PHVS), a promising player in the healthcare sector, has garnered significant attention from investors due to its focus on developing therapies for rare diseases, particularly those unmet needs..

Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Exploring the 159.89% Upside Potential

Taysha Gene Therapies, Inc. (TSHA), a clinical-stage biotechnology company, is making waves in the healthcare sector with its innovative approach to gene therapy. Headquartered in Dallas, Texas, and incorporated in..

Stoke Therapeutics, Inc. (STOK) Stock Analysis: Strong Buy Ratings and a Potential 37.75% Upside

Stoke Therapeutics, Inc. (NASDAQ: STOK) is garnering attention in the biotechnology sector with its innovative approach to treating severe genetic diseases. Leveraging its proprietary TANGO method, Stoke Therapeutics focuses on..

GH Research PLC (GHRS) Stock Analysis: A Biotech with 169% Potential Upside

GH Research PLC (NASDAQ: GHRS), a promising contender in the healthcare sector, specifically in biotechnology, offers a unique proposition for investors seeking exposure to innovative treatments in mental health. Based..

Maze Therapeutics, Inc. (MAZE) Stock Analysis: A Biotech with a 125% Upside Potential

Maze Therapeutics, Inc. (NASDAQ: MAZE) has been gaining attention in the biotech sector as a clinical-stage biopharmaceutical company that focuses on developing precision medicines for kidney and metabolic diseases. With..

Talkspace, Inc. (TALK) Stock Analysis: High Revenue Growth and a Promising 18.73% Potential Upside

Talkspace, Inc. (TALK), a prominent player in the virtual behavioral healthcare sector, is capturing investor attention with its robust revenue growth and significant potential upside. With a current market capitalization..

AMN Healthcare Services Inc (AMN) Stock Analysis: Unlocking a Potential 22% Upside in the Healthcare Sector

AMN Healthcare Services Inc (AMN), a significant player in the healthcare staffing and workforce solutions sector, commands investor attention with its robust operational framework and promising growth potential. Based in..

Community Health Systems, Inc. (CYH) Stock Analysis: Navigating the 21.62% Potential Upside Amidst Challenges

Community Health Systems, Inc. (NYSE: CYH) is a significant player in the healthcare sector, specializing in medical care facilities across the United States. With a market capitalization of $410.33 million,..

Orthofix Medical Inc. (OFIX) Investor Outlook: Unveiling a 49.61% Upside Potential

Investors looking for opportunities in the medical device sector may find Orthofix Medical Inc. (NASDAQ: OFIX) an intriguing prospect. Headquartered in Lewisville, Texas, this healthcare company operates globally, focusing on..

Inventiva S.A. (IVA): Analyst Ratings Signal Significant Upside Potential for Biotech Innovator

Inventiva S.A. (NASDAQ: IVA), a burgeoning player in the biotechnology sector, is capturing investor attention with its robust growth potential and promising pipeline. Headquartered in Daix, France, the company operates..

Akebia Therapeutics, Inc. (AKBA) Investor Outlook: Potential Upside of Over 218% with a Focus on Kidney Disease Treatments

Akebia Therapeutics, Inc. (NASDAQ: AKBA) is gaining attention from investors, particularly those interested in the healthcare sector’s drug manufacturing niche. As a biopharmaceutical company headquartered in Cambridge, Massachusetts, Akebia is..

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: Unveiling a 52.51% Potential Upside for Investors

Amylyx Pharmaceuticals, Inc. (AMLX), a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, is making waves in the healthcare sector, specifically in the niche of drug manufacturers specializing in both specialty and generic..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds